4 known cases. View patent page →
Declaratory-judgment action listing the '219 patent among patents in the case, including 10,272,062; 10,736,866; 10,952,986; 7,851,506; and 8,731,963. Final disposition not confirmed.
Avadel-side Delaware action in which Flamel/Avadel asserted their modified-release GHB patent family, including U.S. 10,272,062 and 10,736,866 (parents of the '986 patent) and U.S. 10,952,986, against Jazz. The case was consolidated and dismissed by order on 2025-10-27 as part of the settlement.
Patent infringement action by Jazz Pharmaceuticals against Avadel CNS Pharmaceuticals concerning sodium oxybate/LUMRYZ; consolidated with related actions and resolved by a global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.